Skip to main content

Table 2 Characteristics of randomised controlled trials of moxibustion vs. sham or other treatments for irritable bowel syndrome

From: Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis

Study (year) Country

Sample size (% female)

Diagnostic criteria used for IBS

Type of IBS (based on the predominant stool form)

Criteria used to define symptom improvement

Moxa intervention (duration)*

Control intervention (duration)

Risk of bias assessmenta

Moxa/AT vs. sham moxa/AT

Anastasi (2009) USA [18]

29 (66%)

Rome III and negative GI investigations

Unspecified

Changes in CGIS

Moxa and AT (4 weeks): Indirect and individualised, twice weekly

Sham moxa and sham AT (4 weeks): Superficial needling at non-acupoints/moxa above and away from acupoints

U-U-Y-Y-U-Y

Moxa/AT vs. pharmacological medications

Chen (2011) China [19]

59 (53%)

Rome III, negative GI investigations and TCM criteria

D 100%

≥ 30% improvement in global IBS symptoms

Moxa and AT (3 weeks): Indirect and partially individualised, o.d., 5 sessions/course, 3 courses in total

Medication (3 weeks):

Y-Y-N-N-Y-Y

- Smecta 1 bag/time b.d.

- Loperamide 4 mg/time t.i.d. and pinaverium bromide 50 mg/time t.i.d. if diarrhea did not stop

Zeng (2010) China [35]

65 (58%)

Rome III

D 100%

≥ 50% improvement in global IBS symptoms

Moxa and AT (1 month): Indirect and partially individualized, o.d., 10 sessions/course in dog days

Medication (1 month): Trimebutine maleate 100 mg/time, t.i.d.

Y-Y-N-N-Y-Y

Xue (2009) China [34]

200 (51%)

Rome II and TCM criteria

Unspecified

Any improvement in global IBS symptoms

Moxa and AT (23–49 days): Fixed, o.d. for 10 sessions (1 course), 2–4 courses in total, with 3 days of no TX interval

Medication (23–49 days): Sulfasalazine 10 mg/kg, o.d. for 10 days (1 course), 2–4 courses in total

U-U-N-N-Y-Y

Wang (2008) China [31]

110 (unspecified)

Rome II

D 100%

≥ 30% improvement in global IBS symptoms

Warming needle (23 days): Fixed, o.d. for 10 sessions (1 course), 2 courses in total, with 3 days of no TX interval

Medication (23 days): Smecta, 1 bag/time t.i.d.

U-U-N-N-Y-Y

Moxa plus other treatments vs. other treatments

Hu (2012) China [21]

64 (22%)

Rome III, negative GI investigations and TCM criteria

D 100%

≥ 30% improvement in global IBS symptoms

Moxa and AT (8 weeks):

AT (8 weeks): Partially individualized, o.d., 5 sessions/week, 20 sessions/course, 2 courses in total

Y-U-N-N-Y-Y

- Moxa: indirect and partially individualized, o.d., 5

sessions/week, 20 sessions/course, 2 courses in total

- AT: partially individualized, o.d., 5 sessions/week, 20 sessions/course, 2 courses in total

Shang (2012) China [29]

48 (58%)

Rome II and negative GI investigations

D 100%

Any improvement in global IBS symptoms

Moxa/AT and medication (30 days): Indirect and fixed, o.d., 10 sessions/course, 3 courses in total

Medication and dietary advice (30 days):

U-U-N-N-Y-Y

- GI antispasmodic drugs, antidiarrheal drugs, anti-anxiety drugs, and intestinal flora regulating drugs

Jiang (2010) China [23]

60 (57%)

Rome II and negative GI investigations

D 100%

Any improvement in global IBS symptoms

Moxa and medication (4 weeks):

Medication (4 weeks): Trimebutine 0.2 g/time, t.i.d.

U-U-N-N-U-N

- Moxa: ginger-partitioned and fixed, o.d. for 7 sessions (1 course), 4 courses in total, with 1 day of no TX interval

- Medication: Trimebutine 0.2 g/time, t.i.d.

Wang (2009) China [30]

60 (55%)

Rome II and TCM criteria (liver-qi stagnation with spleen deficiency type)

D 100%

Any improvement in global IBS symptoms

Moxa and herbal medicine (1 month):

Herbal medicine (1 month): Partially individualised

U-U-N-N-Y-Y

- Moxa: indirect and fixed, o.d.

- Herbal medicine: partially individualised

Xiong (2008) China [33]

120 (60%)

Rome II, negative GI investigations and TCM criteria (liver-qi stagnation with spleen deficiency type)

D 100%

≥ 30% improvement in global IBS symptoms

AT/warming needle and herbal medicine (4 weeks):

Herbal medicine (4 weeks): Fixed, b.d.

U-U-N-N-Y-Y

- AT/warming needle: fixed, no information on sessions

- Herbal medicine: fixed, b.d.

Huang (2007) China [22]

61 (unspecified)

Rome III, negative GI investigations and TCM criteria

Unspecified

Any improvement in global IBS symptoms

Moxa and colon hydrotherapy (4 weeks):

Colon hydrotherapy (4 weeks): Twice weekly for constipation, once weekly for diarrhea

U-U-N-N-Y-Y

- Indirect and partially individualized, o.d.

- Colon hydrotherapy: twice weekly for constipation, once weekly for diarrhea

Liu (1997) [24] China

150 (41%)

Only stated that “all participants had IBS and no organic GI disease”

Unspecified

Any improvement in global IBS symptoms

AT/moxa and psychotherapy (10–75 days): Individualised AT followed by indirect and fixed moxa, once every other day for 10 sessions (1 course), 1–6 courses, with 3–5 days of no TX interval

Psychotherapy (7–42 days): 1–2 sessions/week (1 course), 1–6 courses, each session performed ahead of AT

Y-U-N-N-N-Y

Moxa/AT vs. probiotics

An (2010) China [17]

81 (62%)

Rome II

Unspecified

≥ 30% improvement in global IBS symptoms

Moxa and AT (4 weeks): Indirect and fixed, o.d. for 12 sessions (1 course), 2 courses in total, with 3 days of no TX interval

Bifid triple viable capsules (4 weeks): Bifidobacterium longum, Lactobacillus acidophillus, and Enterococcus faecalis 420 mg (2 capsules)/time, t.i.d.

Y-U-N-N-Y-Y

  1. aRisk of bias was evaluated for 6 criteria in order [11], i.e. sequence generation, allocation concealment, blinding of participants, blinding of outcome assessors, incomplete outcome data, and selective outcome reporting. Each criterion was scored as yes (Y), no (N), or unclear (U), where Y indicates a low risk of bias, N indicates a high risk of bias and U indicates an unclear risk of bias.
  2. *Moxibustion method was classified into three categories on the basis of the levels of individualisation: “fixed” means all patients receive the same treatment at all sessions, “partially individualised” means using a fixed set of points to be combined with a set of points to be used flexibly, and “individualised” means each patient receives a unique and evolving diagnosis and treatment [38].
  3. AT, acupuncture; b.d., twice a day; CGIS, 7-point Likert-type Clinical Global Impression Scale; D, diarrhea-predominant subtype of IBS; GI, gastrointestinal; GP, general practitioner; IBS, irritable bowel syndrome; moxa, moxibustion; o.d., once a day; SSS, severity scoring system; TCM, traditional Chinese medicine; t.i.d., three times a day; TX, treatment.